Dr Mehmi on the Rationale for Investigating Fianlimab/Cemiplimab in Advanced Melanoma
Source: OncLive, September 2023
Inderjit Mehmi, MD, medical oncologist, Cedars-Sinai The Angeles Clinic and Research Institute, discusses the rationale for investigating the combination of fianlimab (REGN3767) and cemiplimab (Libtayo) in patients who have advanced melanoma with poor-risk features.
At the 2023 ASCO Annual Meeting, investigators presented updated results from an exploratory subgroup analysis of an open label, non-randomized, phase 1 clinical trial (NCT03005782) examining the combination. Investigators found that fianlimab and cemiplimab produced clinical activity in patients with advanced melanoma who have characteristics associated with poor prognosis. These characteristics include the presence of liver metastases, elevated LDH grade, and M1c stage disease.
Moreover, the combination of fianlimab and cemiplimab was found to have a safety profile consistent with that of single-agent cemiplimab, as well as other PD-1/PD-L1 treatment options. However, a higher grade of adrenal insufficiency was noted with the use of this doublet.